Anne Schreuder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Schreuder has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Sylvie M. Noordermeer
Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
3 shared publications - Andrea Giovanni Murachelli
Netherlands Cancer Institute and Oncode Institute, Amsterdam, The Netherlands
1 shared publication - Annouche Den Hollander
Leiden University Medical Center (LUMC) Department of Human Genetics Einthovenweg 20, 2333 ZC Leiden
1 shared publication Carlo G.V. Dorresteijn
Leiden University Medical Center, Department of Human Genetics, Leiden, The Netherlands
1 shared publicationIlse Nootenboom
Leiden University Medical Center, Department of Human Genetics, Leiden, The Netherlands
1 shared publication- Klaas de Lint
Department of Human Genetics, Amsterdam University Medical Center, Amsterdam, Netherlands
1 shared publication
Latest Publications
- Open Access
- 5 September 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (17)
Profiling BRCA1-BRCT interactions and their functional relevance at amino acid resolution
BRCA1 (breast cancer-associated protein 1) plays a central role in homologous recombination (HR) through interactions with multiple proteins across its various domains. The C-terminal BRCT domains bind HR regulators such as ABRAXAS1, CtIP, and BRIP1, each contributing to distinct, sometimes opposing, functions. While pathogenic mutations frequently cluster within the canonical BRCT phospho-binding pocket, the broader mutational landscape and its functional consequences remain poorly understood. Here, we used a site-saturation mutagenesis library of the BRCT domains to test >4,000 single-residue variants for their ability to bind ABRAXAS1 and CtIP. Using a yeast two-hybrid screen, we systematically assessed these interactions and validated key findings in mammalian cells. The resulting interaction map identified previously uncharacterized residues critical for partner binding and demonstrated their detrimental impact on HR. Importantly, we identified separation-of-function mutations that selectively disrupt individual protein interactions, enabling a more detailed analysis of each partner’s contribution to HR. Functional assays suggested that disruption of CtIP binding had the most pronounced impact on HR. Furthermore, integration of our data with clinical variant data revealed a strong correlation between loss of protein binding and pathogenicity, highlighting the potential utility of our interaction map for clinical variant interpretation.
- 5 September 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (17)
Open AccessProfiling BRCA1-BRCT interactions and their functional relevance at amino acid resolution
BRCA1 (breast cancer-associated protein 1) plays a central role in homologous recombination (HR) through interactions with multiple proteins across its various domains. The C-terminal BRCT domains bind HR regulators such as ABRAXAS1, CtIP, and BRIP1, each contributing to distinct, sometimes opposing, functions. While pathogenic mutations frequently cluster within the canonical BRCT phospho-binding pocket, the broader mutational landscape and its functional consequences remain poorly understood. Here, we used a site-saturation mutagenesis library of the BRCT domains to test >4,000 single-residue variants for their ability to bind ABRAXAS1 and CtIP. Using a yeast two-hybrid screen, we systematically assessed these interactions and validated key findings in mammalian cells. The resulting interaction map identified previously uncharacterized residues critical for partner binding and demonstrated their detrimental impact on HR. Importantly, we identified separation-of-function mutations that selectively disrupt individual protein interactions, enabling a more detailed analysis of each partner’s contribution to HR. Functional assays suggested that disruption of CtIP binding had the most pronounced impact on HR. Furthermore, integration of our data with clinical variant data revealed a strong correlation between loss of protein binding and pathogenicity, highlighting the potential utility of our interaction map for clinical variant interpretation.
- Open Access
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
With the recent rise in CRISPR/Cas9-mediated genome-wide synthetic lethality screens, many new synthetic lethal targets have been identified for diseases with underlying genetic causes such as tumours with BRCA1 mutations. Such screens often use full deficiency of a protein to identify novel vulnerabilities. However, patient-derived mutations not only result in loss of the protein but often also concern missense mutations with hypomorphic phenotypes. Here we study the genetic vulnerabilities of two previously described hypomorphic BRCA1 missense mutations and compare these to a BRCA1-depleted setting to study whether this affects screening for synthetic lethal interactions. Our research showed that BRCA1 I26A mutated cells have very similar vulnerabilities to BRCA1 wildtype cells, confirming its low tumorigenic effect. In contrast, the BRCA1 R1699Q mutation induced a more similar phenotype to BRCA1-deficient cells. For this mutation, we also unveiled a unique vulnerability to the loss of NDE1. Specifically in BRCA1 R1699Q mutated cells, and not BRCA1-proficient or -deficient cells, NDE1 loss leads to increased genomic instability. Altogether our findings highlight the importance to differentiate between patient-derived mutations when assessing novel treatment targets.
Open AccessFinding novel vulnerabilities of hypomorphic BRCA1 alleles
With the recent rise in CRISPR/Cas9-mediated genome-wide synthetic lethality screens, many new synthetic lethal targets have been identified for diseases with underlying genetic causes such as tumours with BRCA1 mutations. Such screens often use full deficiency of a protein to identify novel vulnerabilities. However, patient-derived mutations not only result in loss of the protein but often also concern missense mutations with hypomorphic phenotypes. Here we study the genetic vulnerabilities of two previously described hypomorphic BRCA1 missense mutations and compare these to a BRCA1-depleted setting to study whether this affects screening for synthetic lethal interactions. Our research showed that BRCA1 I26A mutated cells have very similar vulnerabilities to BRCA1 wildtype cells, confirming its low tumorigenic effect. In contrast, the BRCA1 R1699Q mutation induced a more similar phenotype to BRCA1-deficient cells. For this mutation, we also unveiled a unique vulnerability to the loss of NDE1. Specifically in BRCA1 R1699Q mutated cells, and not BRCA1-proficient or -deficient cells, NDE1 loss leads to increased genomic instability. Altogether our findings highlight the importance to differentiate between patient-derived mutations when assessing novel treatment targets.
- Open Access
- 23 May 2024
- Published by Elsevier in Trends in Genetics
- Vol. 40 (9) , 757-771
(Single-stranded DNA) gaps in understanding BRCAness
- 23 May 2024
- Published by Elsevier in Trends in Genetics
- Vol. 40 (9) , 757-771
Open Access(Single-stranded DNA) gaps in understanding BRCAness